12:00 AM
 | 
Aug 17, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

MEDI-547: Phase I started

AstraZeneca's MedImmune Inc. subsidiary began an open-label, dose-escalation, U.S. Phase I trial to evaluate intravenous MEDI-547 given either once weekly or once every...

Read the full 93 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >